HCG

In a three-week study in healthy men with experimentally induced gonadotropin suppression, hCG maintained intratesticular testosterone in a dose-dependent manner (intratesticular testosterone was suppressed 94% by testosterone/placebo alone but restored toward baseline as the hCG dose increased). The trial did not demonstrate preserved sperm production, fertility or recovery of the hypothalamic-pituitary axis, and it did not involve men using non-prescribed (anabolic) androgens.^[1]

• Short surrogate-endpoint experiment; intratesticular testosterone is not a pregnancy or spermatogenesis outcome.
• This trial used healthy men with experimentally induced (not anabolic-steroid-induced) suppression; it is a different population and design from newer, much more limited real-world reports of hCG in men who continue non-prescribed androgen use (see general-hcg-harmreduction-outcomes-2025), which have their own substantial limitations.
• Abstract-checked; full paper not confirmed open access as of 2026-09-09. No qualified clinical review.

A small, uncontrolled 2025 retrospective report from a single Dutch harm-reduction clinic described increased total and total motile sperm-count measures after hCG treatment in 19 men who continued using non-prescribed androgens; most who produced sperm reached a normal total motile sperm count, while others remained oligospermic or azoospermic. Two independent published commentaries noted the absence of a control group and of sperm-morphology and endocrine data, and this report does not establish that continuing androgen use alongside hCG is a validated, safe or generally appropriate approach; published expert commentary on this report stated that stopping androgen use remains the first-line approach in the broader literature.^[2][3][4]

• Retrospective, uncontrolled case series (n=19) from one clinic, with no matched comparison group; cannot establish that hCG, rather than natural variation, partial cessation, or unmeasured factors, caused the observed change.
• Participants were self-selected: men who had already chosen to continue non-prescribed androgen use and sought care at a harm-reduction clinic. This is not a representative sample of androgen users, and the findings cannot be generalized beyond this specific clinical context.
• The measured outcome was a semen-parameter biomarker (sperm count and motile sperm count), not a pregnancy, live-birth, or fertility-restoration outcome; sperm morphology and endocrine parameters (FSH, LH, estradiol, SHBG) were not assessed.
• Short observation window without long-term follow-up; heterogeneous hCG dosing across participants without a dose-response analysis; all participants continued a testosterone maintenance dose, so results may not generalize to men undergoing high-dose cycling.
• This is a description of a published research finding for evidence-tracking purposes only; it is not treatment guidance, and no dosing, monitoring or regimen information is reproduced here. No qualified clinical review.

A 2026 Dutch retrospective cohort of 35 men with hypogonadotropic hypogonadism and azoospermia found spermatogenesis induced in 74% overall; 25 of 32 (78%) receiving combined hCG-and-FSH-containing gonadotropin therapy achieved spermatogenesis, compared with 1 of 3 receiving hCG alone, a group too small for a reliable comparison. Most who produced sperm improved their semen category, and most who wanted children achieved pregnancy, mostly through spontaneous conception. This is a disease population (hypogonadotropic hypogonadism), not men recovering from anabolic-androgenic steroid exposure.^[5]

• Retrospective single-center cohort with non-standardized follow-up and semen-sampling timing; potential selection and recall bias.
• The hCG-monotherapy comparison group (n=3) is too small to support a reliable percentage comparison against the 32-patient combination-therapy group.
• Disease population (congenital/acquired hypogonadotropic hypogonadism); does not establish outcomes in men recovering from anabolic-androgenic steroid use. No qualified clinical review.